2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1209

Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton’s Tyrosine Kinase
Abstract Number: 2759

Anti-TNF Treatment for Refractory Vascular Involvement of Behçet’s Syndrome
Abstract Number: 1741

Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells in Spondyloarthritis Regardless of Concomittant Gut Inflammation
Abstract Number: 929

Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study
Abstract Number: 2019

Antibodies to Citrullinated Clusterin, Filaggrin, Vimentin, and Fibrinogen Are Associated with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis
Abstract Number: 2539

Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Abstract Number: 1620

Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)
Abstract Number: 1743

Antigen-Specificity Regulates Peripheral Homeostasis of Regulatory T Cells
Abstract Number: 871

Antimalarials Regulate TLR7/8 Mediated Macrophage Activation Via Epigenetic Modification at the TNFα Promoter
Abstract Number: 1308

Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 10

Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients
Abstract Number: 1702

Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?
Abstract Number: 2867

Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps: a New Mechanism of Thrombosis in the Antiphospholipid Syndrome
Abstract Number: 2868

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Initial Analysis
Abstract Number: 17

Antiphospholipid Syndrome Following Infection: A Systematic Review of Case Reports

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].